Filtern
Volltext vorhanden
- ja (5)
Gehört zur Bibliographie
- ja (5)
Dokumenttyp
Sprache
- Englisch (5)
Schlagworte
- hypophosphatasia (2)
- ALPL (1)
- B cells (1)
- CRMO (1)
- HPP (1)
- HRQOL (1)
- TNAP (1)
- alkaline phosphatase (1)
- antinuclear antibodies (1)
- asfotase alfa (1)
- chronic non-bacterial osteomyelitis (1)
- craniosynostosis (1)
- double negative B cells (1)
- juvenile idiopathic arthritis (1)
- medicine (1)
- mineralization (1)
- nervous system (1)
- osteomalacia (1)
- physical activity (1)
- rare bone disease (1)
- rickets (1)
- synovial fluid (1)
- teeth (1)
- zebrafish (1)
Juvenile idiopathic arthritis (JIA) encompasses a heterogeneous group of diseases. The appearance of antinuclear antibodies (ANAs) in almost half of the patients suggests B cell dysregulation as a distinct pathomechanism in these patients. Additionally, ANAs were considered potential biomarkers encompassing a clinically homogenous subgroup of JIA patients. However, in ANA+ JIA patients, the site of dysregulated B cell activation as well as the B cell subsets involved in this process is still unknown. Hence, in this cross-sectional study, we aimed in an explorative approach at characterizing potential divergences in B cell differentiation in ANA+ JIA patients by assessing the distribution of peripheral blood (PB) and synovial fluid (SF) B cell subpopulations using flow cytometry. The frequency of transitional as well as switched-memory B cells was higher in PB of JIA patients than in healthy controls. There were no differences in the distribution of B cell subsets between ANA- and ANA+ patients in PB. However, the composition of SF B cells was different between ANA- and ANA+ patients with increased frequencies of CD21\(^{lo/−}\)CD27\(^−\)IgM\(^−\) “double negative” (DN) B cells in the latter. DN B cells might be a characteristic subset expanding in the joints of ANA+ JIA patients and are potentially involved in the antinuclear immune response in these patients. The results of our explorative study might foster further research dissecting the pathogenesis of ANA+ JIA patients.